Suppr超能文献

格列本脲在固体分散体系统中的体外和体内评价。

In vitro and in vivo evaluation of glibenclamide in solid dispersion systems.

作者信息

Tashtoush Bassam M, Al-Qashi Zubaida S, Najib Naji M

机构信息

Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.

出版信息

Drug Dev Ind Pharm. 2004 Jul;30(6):601-7. doi: 10.1081/ddc-120037491.

Abstract

The purpose of this work is to improve the dissolution and bioavailability characteristics of glibenclamide as compared to Daonil tablets (Hoechst). Solid dispersions of glibenclamide in Gelucire 44/14 (Formula 1) and in polyethylene glycol 6000 (PEG 6000) (Formula 2) were prepared by fusion method. In vitro dissolution studies showed that the dispersing systems containing glibenclamide and Gelucire 44/ 14 or PEG 6000 gave faster dissolution rates than the reference product Daonil. The in vivo bioavailability study was assessed in six healthy male volunteers in crossover design with a 1-week washout period. Both formulas were found to be significantly different from Daonil with regard to the extent of absorption as indicated by the area under serum concentration-time curve. Both formulas are not significantly different from Daonil with respect to time of peak plasma concentration Tmax. It is concluded from this pilot study that the ranking of the in vitro dissolution is similar to the ranking of in vivo availability. The ranking of the three preparations in term of dissolution rate and extent of absorption is as follows: Formula 2>Formula 1 >Daonil.

摘要

本研究的目的是与达美康片(赫斯特公司生产)相比,改善格列本脲的溶出度和生物利用度特性。采用熔融法制备了格列本脲在Gelucire 44/14(配方1)和聚乙二醇6000(PEG 6000)(配方2)中的固体分散体。体外溶出度研究表明,含有格列本脲和Gelucire 44/14或PEG 6000的分散体系的溶出速率比参比产品达美康更快。在交叉设计中,对6名健康男性志愿者进行了体内生物利用度研究,洗脱期为1周。血清浓度-时间曲线下面积表明,两种配方在吸收程度方面均与达美康有显著差异。两种配方在达峰时间Tmax方面与达美康无显著差异。从这项初步研究可以得出结论,体外溶出度的排序与体内生物利用度的排序相似。三种制剂在溶出速率和吸收程度方面的排序如下:配方2>配方1>达美康。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验